Jamila Hokanson, Paul Liknaitzky
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psilocybin study shows personality changes and increased self-compassion in alcohol use disorder patients. Larger studies needed to confirm impact on AUD outcomes.
Broc A Pagni
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.
Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby